Compare Navan Inc. Class A Common Stock (NAVN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Navan Inc. Class A Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Navan Inc. Class A Common Stock trades at $23.66 (market cap $6.22B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Navan Inc. Class A Common Stock is the larger of the two by market cap, and Navan Inc. Class A Common Stock is more actively traded (2,173,244 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Navan Inc. Class A Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NAVN | TVTX | |
|---|---|---|
Market Cap | $6.22B | $4.88B |
Volume | 2,173,244 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $30.58 | $67.52 |
52-Week Low | $8.51 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.57B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Navan (NAVN) trades at $23.9, up 1.44% on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported strong revenue growth of 35% year-over-year in Q2 2027 to $233 million, beating earnings expectations, yet remains unprofitable with a net income margin of -42.11%. Recent developments include the acquisition of BoomPop and a partnership with Engine to expand its AI-powered travel platform.
The outlook is mixed: unanimous analyst buy ratings and a $30.56 price target suggest 27.5% upside, driven by growth execution. However, high debt, persistent losses, insider selling, and ongoing legal investigations pose significant risks. The stock's valuation appears stretched given current profitability challenges.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Navan Inc. Class A Common Stock
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
